Valuation: Daxor Corporation

Market Cap 61.77M 53.99M 49.93M 45.82M 86.72M 5.95B 88.22M 595M 234M 2.91B 232M 227M 10.03B P/E 2026 *
-50.5x
P/E 2027 * -353x
Enterprise Value 61.77M 53.99M 49.93M 45.82M 86.72M 5.95B 88.22M 595M 234M 2.91B 232M 227M 10.03B EV / Sales 2026 *
5.19x
EV / Sales 2027 * 2.97x
Free-Float
46.74%
Yield 2026 *
-
Yield 2027 * -
1 week+1.05%
Current month+2.96%
1 month+9.62%
3 months+12.41%
6 months-22.63%
Current year-28.14%
1 week 10.11
Extreme 10.1101
11.19
1 month 9.37
Extreme 9.3666
11.19
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 2012-12-31
Director of Finance/CFO 69 2018-09-27
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 91 1988-12-31
Chairman 56 2017-02-13
Director/Board Member 61 2017-02-13
Change 5-day change 1-year change 3-year change Capi.($)
-0.94%+0.10%+11.58%+8.72% 61.77M
-1.65%-3.09%+17.61%+98.03% 14.5B
-3.05%-6.25%+41.14%+112.13% 11.71B
+1.04%+2.20%-4.88%+34.02% 9.18B
+0.46%-1.53%-12.85%-12.57% 7.55B
-2.19%-4.49%+27.14%+110.15% 7.4B
-2.27%-1.72%+16.11%+59.74% 6.57B
+0.77%+2.49%+13.50%+27.78% 4.83B
+0.09%+1.48%+14.13%+8.97% 4.16B
0.00%+1.37% - - 3.83B
Average -0.81%+0.34%+13.72%+49.66% 7.75B
Weighted average by Cap. -1.10%-0.12%+15.56%+65.66%

Financials

2026 *2027 *
Net sales 11.9M 10.4M 9.62M 8.83M 16.71M 1.15B 17M 115M 45.07M 560M 44.69M 43.71M 1.93B 20.8M 18.18M 16.81M 15.43M 29.2M 2B 29.71M 201M 78.77M 979M 78.11M 76.4M 3.38B
Net income -1.2M -1.05M -970K -890K -1.68M -116M -1.71M -11.57M -4.54M -56.47M -4.51M -4.41M -195M -200K -175K -162K -148K -281K -19.27M -286K -1.93M -757K -9.41M -751K -735K -32.49M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
-
Date Price Change Volume
26-07-16 $10.50 -0.94% 432
26-07-15 $10.60 -0.47% 1,817
26-07-14 $10.65 +5.34% 1,398
26-07-13 $10.11 -3.99% 378
26-07-10 $10.53 +4.15% 228
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.60USD
Average target price
22.50USD
Spread / Average Target
+112.26%

Quarterly revenue - Rate of surprise